Literature DB >> 29474139

Levels of regulatory B cells do not predict serological responses to hepatitis B vaccine.

Maria Bolther1, Karen Lise Dahl Andersen1, Martin Tolstrup1, Kumar Visvanathan2, Ian Woolley3, Narelle Skinner4, Rosemary Millen4, Nadia Warner5, Lars Østergaard1, Søren Jensen-Fangel1.   

Abstract

This study investigated the immunomodulatory influence of IL10 producing B regulatory cells, Bregs (CD19+CD24hiCD38hi) to standard Twinrix® vaccination. We also investigated HBsAg specific T-cell mediated IFN-γ responses to Twinrix® which in theory could provide effective immunity despite low anti-HBs titer. A total of 309 hepatitis B negative health care students and workers completed a standard Twinrix® vaccination schedule (0, 1 and 6 months). Depending on the vaccination response the participants were divided in to non-, low- and high responders according to anti-HBs titer (<10, <100 and >1000 mIU/mL respectively) two months after completed vaccination schedule. Blood samples from baseline and after vaccination from all non- and low-responders (23 participants) and the same number of high-responders were used for flow cytometric analyses of IL10 producing Bregs and T-cell mediated IFN-γ responses. A decrease in levels of IL10 producing Bregs was observed after vaccination in high responders compared to non- and low-responders. Compiling non-and low-responders against high-responders showed a lower T-cell mediated IFN-γ response at baseline in non-and low-responders when stimulated with Engerix® vaccine. In contrary no positive correlation between IL10 producing Bregs or IFN-γ positive T-cells and anti-HBs titer was observed. Hence this study cannot prove that levels of IL10 producing Bregs or IFN-γ positive T cell affect HBV vaccine response.

Entities:  

Keywords:  Hepatitis B; Interferon γ; Interleukin 10; Twinrix; clinical; flow cytometry; hepatitis; non-responders; vaccinology

Mesh:

Substances:

Year:  2018        PMID: 29474139      PMCID: PMC6037437          DOI: 10.1080/21645515.2018.1441653

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  18 in total

1.  A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults.

Authors:  R W Joines; M Blatter; B Abraham; F Xie; N De Clercq; Y Baine; K S Reisinger; A Kuhnen; D L Parenti
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

2.  Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.

Authors:  W O Böcher; S Herzog-Hauff; J Schlaak; K H Meyer zum Büschenfeld; H F Löhr
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

3.  Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program.

Authors:  Brian J McMahon; Lisa R Bulkow; Rosalyn J Singleton; James Williams; Mary Snowball; Chriss Homan; Alan J Parkinson
Journal:  Hepatology       Date:  2011-07-19       Impact factor: 17.425

4.  The first combined vaccine against hepatitis A and B: an overview.

Authors:  S Thoelen; P Van Damme; A Leentvaar-Kuypers; G Leroux-Roels; M Bruguera; P C Frei; V Bakasenas; A Safary
Journal:  Vaccine       Date:  1999-03-26       Impact factor: 3.641

5.  Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience.

Authors:  P Rendi-Wagner; M Kundi; H Stemberger; G Wiedermann; H Holzmann; M Hofer; K Wiesinger; H Kollaritsch
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

6.  A functional polymorphism in the IL-10 promoter influences the response after vaccination with HBsAg and hepatitis A.

Authors:  Thomas Höhler; Esther Reuss; Christine M Freitag; Peter M Schneider
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

7.  Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses.

Authors:  L Jarrosson; M N Kolopp-Sarda; P Aguilar; M C Béné; M L Lepori; M C Vignaud; G C Faure; C Kohler
Journal:  Vaccine       Date:  2004-09-09       Impact factor: 3.641

8.  Tick-borne encephalitis (TBE) and hepatitis B nonresponders feature different immunologic mechanisms in response to TBE and influenza vaccination with involvement of regulatory T and B cells and IL-10.

Authors:  Erika Garner-Spitzer; Angelika Wagner; Maria Paulke-Korinek; Herwig Kollaritsch; Franz X Heinz; Monika Redlberger-Fritz; Karin Stiasny; Gottfried F Fischer; Michael Kundi; Ursula Wiedermann
Journal:  J Immunol       Date:  2013-07-19       Impact factor: 5.422

9.  What level of hepatitis B antibody is protective?

Authors:  A D Jack; A J Hall; N Maine; M Mendy; H C Whittle
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

10.  Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness.

Authors:  Fernando de la Hoz; Ligia Perez; Marlen de Neira; Andrew J Hall
Journal:  Int J Infect Dis       Date:  2007-10-02       Impact factor: 3.623

View more
  2 in total

1.  Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial.

Authors:  Palittiya Sintusek; Supranee Buranapraditkun; Piyaporn Wanawongsawad; Nawarat Posuwan; Pattarawat Thantiworasit; Nasamon Wanlapakorn; Jettanong Klaewsongkram; Narissara Suratannon; Nataruks Chaijitraruch; Voranush Chongsrisawat; Yong Poovorawan
Journal:  Vaccines (Basel)       Date:  2022-01-08

2.  Hepatitis B Vaccine Non-Responders Show Higher Frequencies of CD24highCD38high Regulatory B Cells and Lower Levels of IL-10 Expression Compared to Responders.

Authors:  Nina Körber; Laureen Pohl; Birgit Weinberger; Beatrix Grubeck-Loebenstein; Andrea Wawer; Percy A Knolle; Hedwig Roggendorf; Ulrike Protzer; Tanja Bauer
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.